Clinical Trials Directory

Trials / Completed

CompletedNCT00117052

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

SENSOR: Study to InvestigatE Cinacalcet TreatmeNt in Haemodialysis Patients With SecOndary HyperparathyRoidism

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
673 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.

Conditions

Interventions

TypeNameDescription
DRUGcinacalcetAll eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.

Timeline

Start date
2004-09-01
Primary completion
2005-11-01
Completion
2006-02-01
First posted
2005-07-04
Last updated
2013-05-23

Source: ClinicalTrials.gov record NCT00117052. Inclusion in this directory is not an endorsement.

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism (NCT00117052) · Clinical Trials Directory